Abstract

The present disclosure relates to a combination therapy comprising co-administration of a relaxin analogue for example, peptide analogues of the B-chain of human relaxin-2 able to activate the RXFP1 receptor and (b) an analogue of vasopressin (also termed arginne vasopressin (AVP), antidiuretic hormone (ADH), and agripressin) able to activate the V1 receptor, for example terlipressin, to an individual in need thereof in the treatment of a renal disorder, such as renal dysfunction in cirrhosis, hepatorenal syndrome type 1 (HRS-AKI) and type 2 (HRS-NAKI), chronic kidney disease and acute kidney injury, and to preserve renal function in peri-operative liver transplantation. This disclosure also relates to compositions comprising relaxin analogues and/or vasopressin analogues for co-administration to an individual in need thereof; preparation of such compositions, and use of such compositions for co-administration to an individual in need thereof, and commercial packages thereto.

IPC Classes  ?

• C07K 14/64 - Relaxins
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids

Abstract

The present disclosure relates to a combination therapy comprising co-administration of a relaxin analogue for example, peptide analogues of the B-chain of human relaxin-2 able to activate the RXFP1 receptor and (b) an analogue of vasopressin (also termed arginine vasopressin (AVP), antidiuretic hormone (ADH), and agripressin) able to activate the V1 receptor, for example terlipressin, to an individual in need thereof in the treatment of a renal disorder, such as renal dysfunction in cirrhosis, hepatorenal syndrome type 1 (HRS-AKI) and type 2 (HRS-NAKI), chronic kidney disease and acute kidney injury, and to preserve renal function in peri-operative liver transplantation. This disclosure also relates to compositions comprising relaxin analogues and/or vasopressin analogues for co-administration to an individual in need thereof; preparation of such compositions, and use of such compositions for co-administration to an individual in need thereof, and commercial packages thereto.

IPC Classes  ?

• C07K 14/64 - Relaxins
• C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
• C07K 7/16 - OxytocinsVasopressinsRelated peptides
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The present disclosure relates to a combination therapy comprising co-administration of a relaxin analogue for example, peptide analogues of the B-chain of human relaxin-2 able to activate the RXFP1 receptor and (b) an analogue of vasopressin (also termed arginine vasopressin (AVP), antidiuretic hormone (ADH), and agripressin) able to activate the V1 receptor, for example terlipressin, to an individual in need thereof in the treatment of a renal disorder, such as renal dysfunction in cirrhosis, hepatorenal syndrome type 1 (HRS-AKI) and type 2 (HRS-NAKI), chronic kidney disease and acute kidney injury, and to preserve renal function in peri-operative liver transplantation. This disclosure also relates to compositions comprising relaxin analogues and/or vasopressin analogues for co-administration to an individual in need thereof; preparation of such compositions, and use of such compositions for co-administration to an individual in need thereof, and commercial packages thereto.

IPC Classes  ?

• C07K 14/64 - Relaxins
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/095 - OxytocinsVasopressinsRelated peptides
• A61K 38/22 - Hormones
• C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
• C07K 7/16 - OxytocinsVasopressinsRelated peptides
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys